Patients should consult with their healthcare provider about appropriate exercise regimens that complement their tirzepatide treatment
GLP-1 helps regulate appetite and blood sugar by: Reducing hunger signals in the brain Slowing gastric emptying Increasing feelings of fullness after meals Originally developed for type 2 diabetes, semaglutide was later shown at higher doses to produce significant, sustained weight loss
Which medication has more side effects
Its role in dermatology has also expanded, particularly for folliculitis, impetigo, and secondary bacterial infections complicating chronic skin disorders
Transitioning from Oral to Injectable: Many patients start with oral semaglutide then switch to injectable forms when: Weight loss plateaus at 5-10 pounds Results are disappointing Tired of daily medication routine Built confidence with GLP-1 therapy Insurance or financial situation changes Switching Process: Stop oral semaglutide Wait one week Start injectable semaglutide at 0.25 mg weekly (regardless of oral dose) Escalate dose according to standard protocol Most people successfully transition and appreciate the improved results with weekly injections
This data drives better outcomes
